The trial tested three paths after initial weight loss: staying on the top tolerated dose, stepping down to 5 mg, or stopping and switching to another option.
Recap by typeshit. Video by @haadmd on TikTok.
The digital health doctor shares a take on GLP-1 therapy paired with lifestyle change and digital programs, calling the finding unsurprising.
Novo Nordisk shared the figure from a post-trial analysis of its next-generation experimental drug, with results broken out for women.
Patients moved off weekly Wegovy injections onto a daily pill, and Men's Journal reports one group's weight outcomes stood out from the rest.
A Facebook post says US researchers found pancreatic cells producing GLP-1 on their own. It frames this as a possible built-in appetite and sugar control system, without naming the study.
One user describes switching to a salad plate, stopping when comfortable and boxing leftovers early. Personal habits, not medical advice.
Bloomberg looks at people using untested peptides in hopes of thinking faster, getting an edge or holding off aging.
Loading…